20th week of 2020 patent applcation highlights part 11 |
Patent application number | Title | Published |
20200147206 | STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS - An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pK | 2020-05-14 |
20200147207 | DUAL ANTHRAX-PLAGUE VACCINES THAT CAN PROTECT AGAINST TWO TIER-1 BIOTERROR PATHOGENS, BACILLUS ANTHRACIS AND YERSINIA PESTIS - Bivalent immunogenic compositions against anthrax and plague are disclosed herein. One bivalent immunogenic composition comprises a triple fusion protein containing three antigens, F1 and V from | 2020-05-14 |
20200147208 | PROCESS FOR THE PREPARATION OF ALLERGENIC EXTRACTS - Disclosed herein are methods for the preparation of allergenic extracts. In one embodiment, the methods are carried out without having to adjust the pH of the extraction phase. The methods provide efficient recovery of allergenic extract from allergenic source material. | 2020-05-14 |
20200147209 | ALUM-CONTAINING COATING FORMULATIONS FOR MICRONEEDLE VACCINE PATCHES - Compositions for coating microneedles with aluminum-adjuvanted vaccines are provided comprising an aluminum-containing wet gel suspension selected from aluminum hydroxide wet gel suspension and aluminum phosphate wet gel suspension; a vaccine in an amount effective to stimulate an immune response in a mammal; a sugar, sugar alcohol, or combinations thereof; and a thickener. Some embodiments of the compositions have a viscosity of 500 to 30,000 cps when measured at 100 s | 2020-05-14 |
20200147210 | METHODS AND COMPOSITIONS OF USE OF CD8+ TUMOR INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF - The subject matter disclosed herein is generally directed to CD8+ tumor infiltrating lymphocytes comprising gene signatures associated with response to immunotherapy treatment. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the gene signatures. Specifically, disclosed herein are gene signatures associated with response to checkpoint blockade therapy and immune cell subtypes characterized by said gene signatures. Further disclosed are methods of using said gene signatures and immune cell subtypes. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs enriched for a specific subtype. | 2020-05-14 |
20200147211 | COMBINATION THERAPIES FOR TREATING CANCERS - Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor. | 2020-05-14 |
20200147212 | Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies - Methods are provided herein for determining and administering optimized dosing of therapeutic anti-CD47 agents, in a schedule that provides safe escalation of dose while achieving a therapeutic level in a clinically effective period of time. The methods can comprise the steps of clearance, escalation, and maintenance. In one embodiment the dosing regimen administers an initial (i) sub-therapeutic dose of an anti-CD47 agent or (ii) a cytoreductive therapy to achieve a safe level of circulating tumor cells for subsequent treatment (clearance); escalating the dose of an anti-CD47 agent until a therapeutic dose is reached (escalation); and maintaining the therapeutic dose for a period of time sufficient to reduce tumor cells in the bone marrow of the patient (maintenance). In an alternative dosing regimen, a patient determined to have a safe level of circulating tumor cells at presentation is treated by the steps of escalation and maintenance without initial clearance. | 2020-05-14 |
20200147213 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF - The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration. | 2020-05-14 |
20200147214 | TISSUE FILLER COMPOSITIONS FOR PHOTO-BIOMODULATION AND METHODS FOR ACHIEVING SAME - The present disclosure generally relates to photo-biomodulation composition comprising a tissue filler and to methods for achieving photo-biomodulation. Specifically, but not exclusively, the present disclosure relates to photo-biomodulation compositions which can be injected into a tissue for achieving photo-biomodulation. | 2020-05-14 |
20200147215 | DRUG CONJUGATES WITH PHOTOCLEAVABLE SOLUBILITY MODULATORS - The present invention is directed to a composition suitable for forming an implanted light activated drug depot, methods of making the composition, and methods and systems for using the composition. The composition comprises a plurality of drug conjugates, which comprise a drug molecule and a small solubility modulating portion. The drug conjugates are insoluble upon implantation as a drug depot into a subject, and the drug is preferably soluble once cleaved from the depot. One aspect of the invention is directed to a drug conjugate having a modulating portion that modifies the solubility of the drug conjugate by employing a hydrophobic non-polar moiety. Another aspect of the invention is directed to a drug conjugate having a modulating portion that modifies the solubility of the drug by employing a charged moiety that shifts the isoelectric point of the drug conjugate to a physiological pH. | 2020-05-14 |
20200147216 | DISEASE DETECTION AND TREATMENT THROUGH ACTIVATION OF COMPOUNDS USING EXTERNAL ENERGY - Described herein are compounds for the detection, diagnosis, and treatment of specific diseased tissues, including hyper-proliferative tissues such as tumors, and other tissue diseased with microbial and/or infectious species, using energy-activation methods. In particular, compounds sensitive to externally applied energy, including light and/or ultrasound; that also specifically accumulate in diseased target tissue, are provided. | 2020-05-14 |
20200147217 | FUCOIDAN-BASED THERAGNOSTIC COMPOSITION - The present invention relates to a fucoidan-based theragnostic composition, and more particularly, to preparation and use of a theragnostic composition which uses a conjugate of a fluorescent dye or a photosensitizer and fucoidan, thereby not only allowing for fluorescence imaging diagnosis of lesions for cancer or vascular diseases but also allowing a therapeutic effect thereon to be obtained at the same time. The conjugate obtained by covalent bonding of a fluorescent dye or a photosensitizer and fucoidan, according to the present invention, is not only useful for fluorescence imaging diagnosis of tumor tissues and ophthalmic vascular diseases, but also may exhibit a therapeutic effect on cancer cells and coronary artery smooth muscle cells, and a neovascularization inhibitory effect in ophthalmic diseases. In addition, in a case where photodynamic therapy is further implemented on the conjugate according to the present invention, cancer and vascular diseases may be effectively treated with low adverse effects. | 2020-05-14 |
20200147218 | BORON-10 CONTAINING BIOCOMPATIBLE NANOSTRUCTURES - A method comprises providing a plurality of nanostructures comprising a base material. The plurality of nanostructures are exposed to a first material at a first deposition temperature. The plurality of nanoparticles are exposed to a second material at a second deposition temperature, and exposed to a Boron-10 ( | 2020-05-14 |
20200147219 | METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1 - A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system. | 2020-05-14 |
20200147220 | Active Pharmaceutical Ingredient Carrier and Production Method of the Same - The present invention relates to an active pharmaceutical ingredient carrier and a production method of the same. The active pharmaceutical ingredient carrier includes silica having a volume of a pore with a pore radius of 1 to 100 nm determined by BJH method of 3.0 to 5.0 ml/g, and a peak of a pore radius of 10 to 50 nm determined by BJH method; and an active pharmaceutical ingredient carried by the silica. | 2020-05-14 |
20200147221 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS - Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation. | 2020-05-14 |
20200147222 | ANTISEPTIC AGENT COMPRISING MEGLUMINE OR SALT THEREOF - The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container. | 2020-05-14 |
20200147223 | POLYMERIC PASTE COMPOSITIONS FOR DRUG DELIVERY - This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent. | 2020-05-14 |
20200147224 | COMPOSITION CONTAINING CATIONIC HYDROXYETHYL CELLULOSE - An aqueous solution comprising a cationic polymer dissolved in water, wherein said cationic polymer comprises a hydrophobic quaternary ammonium group covalently attached to a hydroxyethyl cellulose polymer backbone. Also, a method of delivering a drug to a mucosal surface in a living body, said method comprising applying the aqueous solution to said mucosal surface. | 2020-05-14 |
20200147225 | RIFAXIMIN COMPLEXES - There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex. | 2020-05-14 |
20200147226 | PHARMACEUTICAL COMPOSITION AND METHODS OF USES - The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12. | 2020-05-14 |
20200147227 | DRUG-BOUND COMPOUND AND USE THEREOF - The present invention relates to a CPT-bound compound or a pharmaceutically acceptable salt thereof, the CPT-bound compound being obtained by binding CPT (or a CPT derivative) and guanidine to a reduced monosaccharide. The CPT-bound compound enhances solubility and cell permeability of the CPT drug, which makes it possible to effectively deliver CPT to target cells. Therefore, a pharmaceutical composition comprising, as an active ingredient, the CPT-bound compound or a pharmaceutically acceptable salt thereof is expected to be able to effectively treat cancer, in particular, colorectal cancer, even with a low dose of CPT. | 2020-05-14 |
20200147229 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES - The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods. | 2020-05-14 |
20200147230 | TUMOR NECROSIS TARGETING COMPOSITIONS AND METHODS - compositions and methods employ an anti-nucleolin antibody or fragment thereof to specifically target necrotic tumor cells. Thus, and in preferred aspects, compositions and methods may be used to target the tumor microenvironment and cancer cells within such milieu. Also included are methods of targeting necrotic cells with binding agent that specifically binds nucleolin. | 2020-05-14 |
20200147231 | PLASMIN-CLEAVABLE ANTI-INSOLUBLE FIBRIN ANTIBODY-DRUG CONJUGATE - The present invention relates to an antibody-drug conjugate (ADC) and a composition containing the conjugate for use in treating cancer. According to the present invention, provided are an ADC of an antibody specific to insoluble fibrin and a drug in which a linker linking the antibody and the drug has a plasmin cleavage sequence, and a pharmaceutical composition containing the ADC for use in treating cancer. | 2020-05-14 |
20200147232 | BIOCONJUGATES WITH A CONTROLLED DEGREE OF CONJUGATION, THEIR PROCESS OF PREPARATION, AND THE REAGENTS FOR THEIR PREPARATION - Disclosed is a process for preparation of heterogeneous monodisperse mixtures of protein conjugates with a defined degree of conjugation (1-8) obtained by using a tri-functional reagent allowing affinity concentration followed by subsequent simultaneous release-functionalization. | 2020-05-14 |
20200147233 | METHOD FOR KILLING TUMOR CELLS AND COMPOSITION USED THEREFOR - It is an object of the present invention to provide a method for killing tumor cells, having a few side effects. The present invention provides a method for killing tumor cells, comprising:
| 2020-05-14 |
20200147234 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES - The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses. | 2020-05-14 |
20200147235 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. | 2020-05-14 |
20200147236 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF - The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process. | 2020-05-14 |
20200147237 | Complexes of Viral-Based Therapeutic Agents and Modified Poly(Beta-Amino Ester)s - Disclosed are complexes of virus-based therapeutic agents with polymers that are poly(beta-amino ester)s (PBAEs) modified with at least one oligopeptide. Also disclosed are methods of treatment using these complexes and methods of encapsulating said complexes to form nanoparticles. | 2020-05-14 |
20200147238 | SACCHARIDE-BASED, ORAL MUCOADHESIVE DELIVERY SYSTEM FOR PHARMACEUTICAL COMPOSITIONS - The oral cavity is an ideal-site for small molecule, pharmaceutical delivery to the systemic circulation due to the highly-vascularized, oral mucosa, near-neutral pH conditions, and avoidance of gastric degradation and first-pass hepatic metabolism. Accordingly, a novel, saccharide-based, food-form, portable, individually wrapped, oral delivery systems that attaches to the oral mucosa for a longer contact-duration than current orally available formulas resulting in greater, small molecule bioavailability, and a more rapid, therapeutic effect are preferred and described. | 2020-05-14 |
20200147239 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF - The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. | 2020-05-14 |
20200147240 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS - Methods of treatment of complement-mediated disorders, in particular disorders associated with over-activity of the complement C3b feedback cycle (for example, age-related macular degeneration (AMD)), using gene therapy is described. According to the methods, levels of complement Factor I are elevated by administration of a recombinant viral vector encoding Factor I such that a therapeutically effective amount of the encoded Factor I is expressed from the vector in the subject. Recombinant viral vectors encoding Factor I, recombinant virus particles encapsidating the vectors, and their use in the methods of treatment, is also described. | 2020-05-14 |
20200147241 | DISULFIDE BOND STABILIZED POLYPEPTIDE COMPOSITIONS AND METHODS OF USE - Provided herein are polypeptides comprising one or more non-native cysteine residues that form a disulfide bridge between non-native cysteines within the protein or between non-native cysteines of two monomers of the protein. Such modified human polypeptides are useful in treatment of genetic diseases via enzyme replacement therapy and/or gene therapy. | 2020-05-14 |
20200147242 | MAGNETIC, THERMOSENSITIVE, FLUORESCENT MICELLE AND METHOD FOR PREPARING THE SAME - A magnetic, thermosensitive, fluorescent micelle includes a core, a carrier wrapping the core, and a plurality of water-soluble near-infrared CdHgTe quantum dots (QD) disposed on the carrier. The core includes dextran-magnetic layered double hydroxide-fluorouracil (DMF). The carrier includes a tripolymer of poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-polylactic acid (PLA). N-isopropylacrylamide-co-N,N-dimethylacrylamide of the tripolymer includes a hydrophilic group and a hydrophobic carbon frame. The hydrophilic group is oriented outwards with respect to the and forms a shell. The hydrophobic carbon frame and polylactic acid are restrained to wrap the dextran-magnetic layered double hydroxide-fluorouracil to form the core. | 2020-05-14 |
20200147243 | LIGAND COMPOUND OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AND APPLICATION THEREOF - Provided is a ligand compound of α7 nicotinic acetylcholine receptor, which can be represented by any one of the following general formulas, wherein (1) represents a halogen. The ligand compound is an improved ligand compound of α7 nicotinic acetylcholine receptor. The ligand compound can be used as a PET imaging agent after being radio-chemically marked. | 2020-05-14 |
20200147244 | THERANOSTIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING - Disclosed are compounds, compositions, and methods involving theranostic capture agent for a target where the capture agent is (a) a precursor that can be loaded with a detectable moiety, a therapeutic moiety, or both, (b) loaded with a detectable moiety, (c) loaded with a therapeutic moiety, or (d) loaded with both a detectable moiety and a therapeutic moiety. Also disclosed are stable peptide-based PSMA capture agents and methods of use as detection agents. | 2020-05-14 |
20200147245 | GRAPHITE POWDER BASED COUNTER ELECTRODE - A device for providing treatment is disclosed. The device provides proper skin electrical conductivity while still being minimally invasive by adhering to the patient's skin that also implements safety measures that off-the-shelf electrode options do not have. This device includes a graphite powder-based skin counter electrode that has a graphite powder suspended in an electrolyte gel that allows for electrochemical conduction between the graphite particles in the graphite powder. The gel is spread over a first side of a hydrogel layer. A device housing is mounted on the hydrogel layer over the first side. The device housing contains the electrolyte gel and graphite powder, defines an opening or lead opening as well as an empty expansion chamber for gaseous anodic byproduct. A metallic wire or rod extends from the electrolyte gel and through the housing opening and connects to a potentiostat. The second side of the hydrogel layer is adhered to the skin of the patient. The graphite powder-based skin counter electrode device takes into account safety. | 2020-05-14 |
20200147246 | Methods and Systems for the Sterilization of Endoscopes - A method and device for high-pressure, high-temperature steam sterilization of endoscopes includes pressure resistant fittings to attach a steam generator to the ports of an endoscope. The method and device allows for high-pressure, high-temperature steam to circulate throughout the endoscope, exposing various surfaces to steam for sterilization. The method and device also allows for high-pressure, high-temperature steam to circulate selectively through the channels of the endoscope, selectively sterilizing the channels and allowing for use of this method with current high-level disinfection methods. The method and device also allows for movement of the scope elevator channel during the sterilization process, allowing for steam to reach the crevices around the elevator and other moving parts of an endoscope. | 2020-05-14 |
20200147247 | PIPETTE TIP WASHING DEVICE - A washing device comprises a manifold dispenser comprising at least one liquid input and a plurality of liquid outputs that operably direct fluid to contact a plurality of laboratory consumables held by a rack in the washing device. A number of liquid outputs is equal to a number of laboratory consumables such that each one of the fluid outputs operably directs fluid at a corresponding one of the laboratory consumables. | 2020-05-14 |
20200147248 | UV DISINFECTING UNIT - A UV disinfection unit includes a frame, a flexible envelope supported by the frame, the envelope having a reflective inner surface defining an inner volume for receiving an object to be disinfected, and a UV source for being received in the volume. | 2020-05-14 |
20200147249 | AN AUTONOMOUS DISINFECTANT SYSTEM - Described herein is a disinfectant system in the form of an autonomous device for performing a disinfectant operation within an enclosed space defined by the walls, ceiling and floor of a room when a predefined condition, in the form of the absence of a human being within the room, is met. The purpose of the system is environmental decontamination and specifically to inactivate pathogenic organisms. The device includes a disinfectant module for carrying out the disinfectant operation when there is an absence of a human being within the room, and a sensing module for sensing the presence of a substantially stationary human being within the room. | 2020-05-14 |
20200147250 | Closure Mechanisms and Seal Integrity Indicators for Sterilization Containers - Closure mechanisms for closing and sealing sterilization containers and indicators for indicating the seal integrity sterilization containers are provided. For example, a container closure mechanism may be configured to distribute a closure force along a gasket to seal a container lid to a container body. Further, a seal indicator may visibly indicate at the container exterior whether the container is sufficiently sealed to prevent an ingress of contaminants into the container. If the container is sufficiently sealed, the seal indicator is a first state, and if the sterilization container is not sufficiently sealed, the seal indicator is in a second state. Thus, the seal indicator undergoes a state change when the sterilization container transitions from unsealed to sealed or from sealed to unsealed, such that a user can ascertain whether the container is properly sealed to maintain sterility or whether the seal and sterility of the container have been compromised. | 2020-05-14 |
20200147251 | Filtered Product Bag with Compact Form Factor - A product bag includes a bladder and an elongated filtration device. The bladder includes opposing first and second film layers defining a product chamber. The first and second film layers are sealed together along a perimeter seal extending along at least a portion of a perimeter of the bladder. The elongated filtration device includes a housing, a filtration membrane disposed in the housing, an inlet adapted for receiving a fluid to be filtered, and an outlet in fluid communication with the product chamber. A majority of the elongated filtration device is embedded between the first and second film layers of the perimeter seal of the bladder to provide for a compact form factor. | 2020-05-14 |
20200147252 | Seal Integrity Indicator for a Sterilization Container - Seal integrity indicators for sterilization containers are provided. For example, a seal indicator may indicate whether the container is sufficiently sealed to prevent an ingress of contaminants into the container. If the container is sufficiently sealed, the seal indicator is visible, but if not, the seal indicator is not visible. Thus, the seal indicator undergoes a change in state when the sterilization container transitions from unsealed to sealed, or vice versa, such that a user may ascertain whether the container is properly sealed to maintain the container's sterility. An exemplary seal indicator includes an invertible projection formed with the container gasket that is not visible from outside the container until inverted, due to force applied by the lid, to extend through an opening in the container body. Closure mechanisms for sterilization containers also are provided. | 2020-05-14 |
20200147253 | Closure Mechanism and Seal Integrity Indicator for a Sterilization Container - Closure mechanisms and seal integrity indicators for sterilization containers are provided. For example, a closure mechanism comprising at least one handle and at least two arms is provided with a sterilization container lid to apply a more uniform or evenly distributed force to a container gasket. A container body defines an inner lip on which the gasket and lid are received such that the sealing interface is recessed within the container. Further, a seal indicator may indicate whether the container is sufficiently sealed to prevent an ingress of contaminants into the container. If the container is sufficiently sealed, the seal indicator is visible, but if not, the seal indicator is not visible. Thus, the seal indicator undergoes a change in state when the sterilization container transitions from unsealed to sealed, or vice versa, such that a user may ascertain whether the container is properly sealed to maintain the container's sterility. | 2020-05-14 |
20200147254 | DISINFECTION OR STERILIZATION INDICATOR - An indicator device and method for monitoring disinfection or sterilization of closed environments and surfaces located in said closed environments, the disinfection and sterilization made by applying a disinfection or sterilization agent, wherein the indicator device comprises a carrier coated or embedded with substances or reagents that produce a change in color or in other readily visible property when contacting said disinfection or sterilization agent, and wherein the carrier is configured as a polyhedron, a cone, a cylinder, a sphere or any three-dimensional shape. A planar carrier having weakened linear areas or groves, printed lines or printed images, and so it is configured to be folded along said linear areas, groves or printed lines or images so as to form a polyhedron, a cone or a cylinder and so it is configured to be folded along said linear areas, groves or printed lines or images so as to form a polyhedron, a cone or a cylinder. | 2020-05-14 |
20200147255 | DEVICE FOR EVAPORATING VOLATILE SUBSTANCES COMPRISING WICK AND HEAT REFLECTIVE ELEMENT - A device for evaporating volatile substances includes a wick ( | 2020-05-14 |
20200147256 | AROMA CARTRIDGE AND AROMA DISPLAY - An aroma cartridge includes: a housing to be loaded to a cartridge loading section of an aroma display, having a hollow portion to store a scent source therein, and a scent passage for emitting scent from the scent source in the hollow portion to the outside; and a near field communication tag attached to an outer surface of the housing for transmitting, by near field communication, to a near field communication reader, data identifying the scent corresponding to the type of scent source contained in the aroma cartridge. | 2020-05-14 |
20200147257 | HUMIDIFIER WITH REGULAR ADDITION OF FIXED QUANTITY OF ESSENTIAL OIL - A humidifier with regular addition of fixed quantity of essential oil comprises a main body, and a water storage bucket assembling with the main body. The main body comprises an opening located on one side, an inner casing corresponding to the opening, and a peristaltic pump provided on a side of the inner casing not facing the opening. The inner casing defines an essential oil bottle accommodation space communicating with the opening, and the essential oil bottle accommodation space is provided for disposing an essential oil bottle storing an essential oil. The peristaltic pump is controlled by the main body, thereby fixed quantity of essential oil is supplied regularly and quantitatively by the humidifier without dismounting the water storage bucket. Thus, fragrance is kept in atomizing air continuously to solve the problem of the conventional humidifier that fragrance merely exists when the essential oil is added initially. | 2020-05-14 |
20200147258 | Feminine Care Absorbent Article Containing Nanoporous Superabsorbent Particles - A feminine care absorbent article comprising an absorbent member positioned between a topsheet and a baffle is provided. The absorbent member contains at least one layer that comprises superabsorbent particles containing nanopores having an average cross-sectional dimension of from about 10 to about 500 nanometers. | 2020-05-14 |
20200147259 | FORMULATION COMPRISING NANOSTRUCTURED, BIOCOMPATIBLE AND BIOCATALYTIC MATERIAL FOR THE TREATMENT OF WOUNDS AND INFECTIONS - Formulation comprising nanostructured, biocompatible and biocatalytic material comprising a solid acid consisting of mixed oxides of silica and titania (TiO | 2020-05-14 |
20200147260 | METHOD OF PRODUCING PRODUCT INORGANIC COMPOUND AND PRODUCT INORGANIC COMPOUND - A method of producing a product inorganic compound including: immersing a raw material inorganic compound having a volume of 10 | 2020-05-14 |
20200147261 | POROUS MATERIAL AND PROCESS - A porous material suitable for implant is disclosed comprising a large plurality of substantially spherical intercalated hollows in a polymer. The hollows are formed by combining the polymer with a fugitive material under heat and pressure and subsequently removing the fugitive material to reveal the hollows. Intercalation can be increased by subjecting the fugitive material to a coalescing compacting process prior to combining the fugitive material with the polymer. The porous material can be combined with a solid material such as a solid polymer to fabricate complex implantable materials with a variety of features. | 2020-05-14 |
20200147262 | GEL OF SODIUM HYALURONATE CROSS-LINKED BY POLYETHYLENE GLYCOL EPOXY DERIVATIVE FOR INJECTION AND PREPARATION METHOD THEREOF - The present invention discloses polyglycol epoxide crosslinked sodium hyaluronate gel for injection and a preparation method thereof. A polyglycol epoxide is a compound with single molecular weight preferably; a plurality of ether bonds are present in the molecule of the polyglycol epoxide, the water solubility is good, and thus, the polyglycol epoxide is more easily subjected to a crosslinking reaction with polysaccharides; and meanwhile, polyglycol is relatively easy in adjustment of the number of repeating units and relatively easy in control of length, and thus, the sodium hyaluronate gel prepared by taking the polyglycol epoxide as a crosslinker is relatively easy in regulation and control of properties. The crosslinked sodium hyaluronate gel is low in toxicity, little in residual, small in squeezing and pushing force, good in shaping performance, good in enzyme resistance and long in in-vivo retention time. The present invention further discloses a mild crosslinker deactivation technology. Unreacted epoxide groups in the gel are subjected to a hydrolysis reaction in a carbonate buffer system with a pH of 8-9, so that the difficulty of impurity removal of the crosslinked sodium hyaluronate gel can be effectively lowered, and the problem of toxicity in the prior art due to the fact that BDDE is used in a crosslinking method is avoided. | 2020-05-14 |
20200147263 | Cell-free Combination, Hydrogel-like Material or Hydrogel and Use of Same - A cell-free combination for use in the controlled, especially decelerated or retarded, release of active ingredient and/or in the production of a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or as a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or for the coating of a medical product, especially implant, preferably with a formulation in hydrogel form, especially depot formulation in hydrogel form, wherein the cell-free combination comprises a first component and a second component, the first component comprising crosslinkable albumin and the second component comprising a crosslinking agent for the albumin. Additionally, a hydrogel-forming material or hydrogel, to a kit or multicomponent system, to a medical product or a pharmaceutical formulation, to a discharge device, and to uses of the cell-free combination and of the hydrogel-forming material or hydrogel. | 2020-05-14 |
20200147264 | DETECTION OF BIOPROSTHETIC VALVE DEGENERATION - The invention relates to a method for predicting or diagnosing a risk of bioprosthetic valve degeneration. Further, the invention relates to a medical device, in particular a bioprosthetic valve coated with EPCR less prone to degeneration and/or calcification once implanted. | 2020-05-14 |
20200147265 | METHOD FOR CROSSLINKING ARTIFICIAL BIOLOGICAL TISSUE - The present disclosure provides a method for crosslinking an artificial biological tissue. The method may include: providing an artificial biological tissue and crosslinking agent solution, wherein the crosslinking agent includes an imide structure; immersing the artificial biological tissue into the crosslinking agent solution to produce a crosslinking reaction. In this way, the anti-calcification capacity of the crosslinked artificial biological tissue may be improved in the present disclosure. | 2020-05-14 |
20200147266 | Methods for Localized Modification of Tissue Products - Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a cross-linking agent and/or a proteolytic enzyme to produce a tissue matrix with variable mechanical and/or biological properties. | 2020-05-14 |
20200147267 | ENHANCEMENT OF OSTEOGENIC POTENTIAL OF BONE GRAFTS - The present invention concerns the enhancement of the osteogenic potential of bone graft by ex vivo treatment with a Wnt polypeptide, such as a liposomal Wnt polypeptide. | 2020-05-14 |
20200147268 | PROSTHETIC TISSUE VALVE AND METHOD OF PREPARING THE SAME - The present disclosure provides a prosthetic tissue valve and a preparation method thereof. The preparation method consists of a lyophilization process of soaked biological tissues under preset condition to obtain a lyophilized prosthetic tissue valve, which provides a technical support for pre-loading the lyophilized prosthetic tissue valve onto the delivery device immediately after manufacture. The preset conditions may include a cooling process with a cooling rate of which the temperature decreases from room temperature to a lyophilization temperature, the lyophilization temperature of −200° C.-0° C., and a pressure of 1 Pa-102 kPa. In such a way of preparation, the present disclosure can provide a lyophilized prosthetic tissue valve. | 2020-05-14 |
20200147269 | METHODS FOR PRODUCING TRANSPLANTABLE CARTILAGE TISSUE - The present invention relates to a method for producing cartilage tissue by selecting and choosing from chondrocytes or spheroids, and use thereof as pharmaceutical composition, medicinal product or transplant. In particular, the invention relates to markers for identifying suitable chondrocytes for producing cartilage tissue, in particular for the purpose of transplantation. | 2020-05-14 |
20200147270 | METHOD FOR PREPARING INORGANIC NANOPARTICLE-GELATIN CORE-SHELL COMPOSITE PARTICLES - The present disclosure provides a method for preparing inorganic nanoparticle-gelatin core-shell composite nanoparticles, comprising: dissolving gelatin in a aqueous solution (in which inorganic nanoparticles are dispersed in) to obtain the gelatin-contained aqueous solution, dropwise adding a polar organic solvent to obtain a suspension of inorganic nanoparticle-gelatin core-shell composite particles of nanometer size or submicrometer size, then adding a cross-linking agent thereto to cross-link the gelatin components of the composite particles, followed by washing step to finally obtain inorganic nanoparticle-gelatin core-shell composite micro/nano-particles with inorganic nanoparticles as the core and gelatin as the shell. The present invention firstly provides a process for preparing the core-shell composite nano-scaled particles with inorganic nanoparticles as the core and gelatin as the shell by using a co-precipitation method which is simple and convenient, and beneficial for applying to industrial mass production. | 2020-05-14 |
20200147271 | VASCULAR GRAFTS HAVING A MODIFIED SURFACE - Disclosed are vascular grafts having a surface modified to reduce the risk of thrombi formation post implantation into a subject. The vascular graft can include a tubular structure comprising a base polymer admixed with an oligofluorinated additive. | 2020-05-14 |
20200147272 | BIOENGINEERED ALLOGENEIC BLOOD VESSEL - The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases. | 2020-05-14 |
20200147273 | LUBRICIOUS HYDROPHILIC COATINGS AND METHODS OF FORMING THE SAME - Self-crosslinking hydrophilic coatings. | 2020-05-14 |
20200147274 | ELASTOMER MOLDED BODY FOR MEDICAL DEVICE, METHOD OF MANUFACTURING OF ELASTOMER MOLDED BODY FOR MEDICAL DEVICE, AND MEDICAL DEVICE - An elastomer molded body for a medical device includes an elastomer portion and a filler. The elastomer portion contains a crosslinked fluorine-based elastomer. The filler is formed from a plurality of particles each of which has aspect ratio of 5 or more and specific surface area of 3 m | 2020-05-14 |
20200147275 | COPPER BACTERICIDE / VIRUCIDE ASSEMBLY - A copper bactericide/virucide assembly for killing invasive bacteria and viruses in a nostril includes a wire that is comprised of copper. In this way the wire can kill bacteria and viruses on contact. The wire is insertable into a nostril thereby facilitating the wire to contact mucous membranes within the nostril. Thus, the wire can kill invasive microbes, bacteria and viruses on the mucous membranes thereby reducing the likelihood of developing an upper respiratory infection. | 2020-05-14 |
20200147276 | ULTRASONIC CATHETER FOR RENAL DENERVATION - Catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present technology, for example, is directed to a treatment device including a therapeutic assembly having a PVDF transducer. A method for tissue denervation through the application of ultrasonic energy, can include positioning a PVDF transducer within a blood vessel of a patient; applying RF energy to the PVDF transducer thereby causing the PVDF transducer to deliver ultrasonic energy to the tissue; and at least partially denervating tissue that is innervated by neural matter located within or in proximity to the blood vessel via the ultrasonic energy delivered to the tissue. | 2020-05-14 |
20200147277 | SUBSTRATE HAVING AN ELECTRON DONATING SURFACE WITH METAL PARTICLES COMPRISING PALLADIUM ON SAID SURFACE - There is disclosed a substrate with an electron donating surface, characterized in having metal particles on said surface, said metal particles comprising palladium and at least one metal selected from the group consisting of gold, ruthenium, rhodium, osmium, iridium, and platinum, wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm | 2020-05-14 |
20200147278 | SYSTEM AND METHOD FOR COLLECTING EXUDATES - A reduced pressure treatment system includes a porous pad positioned at a tissue site and a canister having a collection chamber, an inlet, and an outlet. The inlet is fluidly connected to the porous pad. A reduced pressure source is fluidly connected to the outlet of the canister to such that fluid from the tissue site may be drawn into the collection chamber. A hydrophobic filter is positioned adjacent the outlet to prevent liquid from exiting the collection chamber through the outlet. A baffle is positioned within the canister to create a tortuous path between the inlet and the outlet to prevent premature blocking of the hydrophobic filter. | 2020-05-14 |
20200147279 | DEVICE AND METHOD FOR CLEARING TUBING - A device for moving contents of a tube by acting on the exterior of the tube is provided. The device includes a housing having a tube passageway extending along a length thereof for holding a tube therein. A first roller and a second roller are moveable between a first position and a second position and configured to compress the tube in the second position. A first roller chassis is coupled to the housing for mounting the first roller therein and a second roller chassis is coupled to the housing for mounting the second roller therein. The first and second roller chasses are moveable between a first position in which the tube is disengaged and a second position in which the tube is engaged. A lever operably coupled to the housing causes the first or second roller to pivot and engage the tube positioned within the passageway. | 2020-05-14 |
20200147280 | Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds - Microstrain-inducing manifolds, systems, and methods are presented that involve microstrain-inducing manifolds that include a plurality of shaped projections for creating microstrain. The shaped projections may be tapered projections. A system may include a sealing member for placing over the tissue site, a microstrain-inducing manifold, and a reduced-pressure subsystem that delivers reduced pressure to the sealing member. The reduced pressure causes the shaped projections to create microstrain at the tissue site. Other methods, apparatuses, and systems are also presented. | 2020-05-14 |
20200147281 | HOLDER FOR A CURVED DUCT PORTION - The holder for a curved duct portion of a tube pump comprises: a supply-side connector comprising a first cavity and a first plate connected together, the first cavity being adapted for receiving an end of the curved duct portion, and a discharge-side connector comprising a second cavity and a second plate connected together, the second cavity being adapted for receiving another end of the curved duct portion, where said connectors are movable the one with respect to the other between a storage configuration, in which the supply-side connector is positioned away to the discharge-side connector, and an operating configuration, in which the supply-side connector is close to the discharge-side connector and in which the first and second plate are engaged together substantially on a same plane. | 2020-05-14 |
20200147282 | REDUNDANT-IMPELLER ARTIFICIAL HEART - An artificial heart for use in a human recipient includes a housing within which a trio of turbine pump segments are operative. Two of the turbine pumps form a series connected pair for redundancy. The redundancy enhances the safety factor provided by the artificial heart. A controller is powered by a rechargeable battery and is operative to apply appropriate drive signals to the motor drives of the turbine pump segments. The battery may be implanted along with the controller to avoid the need for any external connections to the artificial heart. An inductively coupled battery charger for use outside the recipient's body is positioned proximate the battery charger to provide inductively coupled charging for use in driving the artificial heart. | 2020-05-14 |
20200147283 | MOTOR ASSEMBLY FOR CATHETER PUMP - A catheter pump is disclosed herein. The catheter pump can include a catheter assembly that comprises a drive shaft and an impeller coupled to a distal end of the drive shaft. A driven assembly can be coupled to a proximal end of the drive shaft within a driven assembly housing. The catheter pump can also include a drive system that comprises a motor and a drive magnet coupled to an output shaft of the motor. The drive system can include a drive assembly housing having at least one magnet therein. Further, a securement device can be configured to prevent disengagement of the driven assembly housing from the drive assembly housing during operation of the pump. | 2020-05-14 |
20200147284 | METHODS, SYSTEM, AND COMPUTER READABLE MEDIA FOR A ROTATIONAL SPEED-BASED CONTROL SYSTEM FOR VENTRICULAR ASSIST DEVICES - Methods, systems, and computer readable media for controlling ventricular assist devices are disclosed. In some embodiments, the method includes receiving at least one reference pump speed differential associated with a pump of a ventricular assist device; determining a filtered pump speed differential associated with the pump of a ventricular assist device; and adjusting, using a feedback based controller algorithm, current to the pump based on the at least one reference pump speed differential and the filtered pump speed differential. In some embodiments, the system includes a controller implemented using the non-transitory computer readable medium, wherein the controller is configured for receiving at least one reference pump speed differential associated with a pump of a ventricular assist device; determining a filtered pump speed differential associated with the pump of a ventricular assist device; and adjusting current to the pump based on the at least one reference pump speed differential and the filtered pump speed differential. | 2020-05-14 |
20200147285 | HEART SUPPORT SYSTEM, CANNULA ARRANGEMENT FOR A HEART SUPPORT SYSTEM AND USE OF THE HEART SUPPORT SYSTEM - The disclosure relates to a heart support system with at least one system unit that includes a pump arrangement, a first connection apparatus connected to the pump arrangement and a second connection apparatus connected to the pump arrangement, wherein the pump arrangement has a first pump that is fluidically connected in a first flow path between the first and the second connection apparatus. The pump arrangement further has an intermediate reservoir and a second pump, which are connected in series together with the first pump in the first flow path, wherein the intermediate reservoir is fluidically arranged between the first pump and the second pump. The disclosure further relates to a cannula arrangement for a heart support system of this kind and a corresponding use of the heart support system. | 2020-05-14 |
20200147286 | HVAD CIRCADIAN TRACKER (PHI+) - A method of detecting a disruption in a diurnal rhythm of a patient having an implantable blood pump comprising calculating a moving average convergence divergence (MACD) based on power consumed by the implantable blood pump to maintain a constant rotational speed of an impeller of the implantable blood pump and generating an alert when the calculated MACD does not cross a MACD zero line for a predetermined MACD zero line crossing time threshold. | 2020-05-14 |
20200147287 | OPTIMIZED HEMODIALYZER FOR BLOOD PURIFICATION - The present disclosure concerns a hemodialyzer for the purification of blood and use thereof. The hemodialyzer comprises a bundle of hollow fiber membranes, wherein the hollow fiber membranes have an inner diameter (d | 2020-05-14 |
20200147288 | APPARATUS FOR REMOVING CHEMOTHERAPY COMPOUNDS FROM BLOOD - A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject. | 2020-05-14 |
20200147289 | SYSTEMS AND METHODS FOR OPTIMIZATION OF PLASMA COLLECTION VOLUMES - A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure. | 2020-05-14 |
20200147290 | LIMB STABILISATION APPARATUS AND METHODS - A limb-stabilisation apparatus ( | 2020-05-14 |
20200147291 | Blood Purification Apparatus - A blood purification apparatus is provided that is capable of detecting an abnormal state of puncture into a blood vessel with an arterial puncture needle or a venous puncture needle. The blood purification apparatus includes an oscillating device capable of supplying an alternating current at a predetermined frequency and changing the frequency of the alternating current among a plurality of frequencies, a measuring device capable of measuring an impedance for each of the frequencies, a calculating device capable of acquiring an impedance frequency characteristic, a storage device capable of storing an impedance frequency characteristic acquired in a case of normal puncture into the patient's blood vessel with an arterial puncture needle and a venous puncture needle, and an identifying device capable of identifying whether the puncture into the blood vessel with the arterial puncture needle a or the venous puncture needle b is normal in accordance with the change observed between the impedance frequency characteristic acquired by the calculating device and the impedance frequency characteristic stored in the storage device. | 2020-05-14 |
20200147292 | METHOD AND DEVICE FOR INTRAOPERATIVE DETERMINATION OF DRAG COEFFICIENT VALUES OF DIFFERENT MEDICAL INSTRUMENTS IN THE USE OF A MEDICAL FLUID PUMP - Subject matter of the present invention is a method for determining the resistance coefficients in particular of different combinations of shaft and endoscope when using a medical fluid pump, e.g. in the context of arthroscopy. | 2020-05-14 |
20200147293 | SUCTION DEVICE - A suction device includes an outer tube having an inlet at a first end and an inner suction tube located within the outer tube, the inner suction tube having an inlet at a first end corresponding to the first end of the outer tube. The inlet of the inner suction tube is offset by a distance from the inlet of the outer suction tube, such that the inlet of the inner suction tube is located within the outer suction tube. | 2020-05-14 |
20200147294 | SUCTION IRRIGATOR - Disclosed is a suction irrigator, including a tri-lumen tube which includes a normal-pressure irrigation lumen, a high-pressure irrigation lumen and a suction lumen, a manifold connected to the tri-lumen tube, two flexible tubes, a control unit and a dual-drainage tube connected to the two flexible tubes, where the cross-sectional area of the suction lumen is larger than that of the normal-pressure irrigation lumen, and the cross-sectional area of the normal-pressure irrigation lumen is larger than that of the high-pressure irrigation lumen; and the normal-pressure irrigation lumen and the high-pressure irrigation lumen are connected to one of the flexible tubes and the suction lumen is connected to the other flexible tube by means of the manifold; and flow rates of gas or liquid in the two flexible tubes are controlled by the control unit. The suction irrigator has a good irrigation effect and is convenient to use. | 2020-05-14 |
20200147295 | BALLOON-IN-BALLOON IRRIGATION BALLOON CATHETER - An irrigation balloon catheter includes one or more inner balloons inside of an irrigation balloon. The inner balloon(s) can be compliant with a volume that is dynamically adjustable for rapid inflation, rapid deflation, complete deflation, and/or irrigation flow adjustment. | 2020-05-14 |
20200147296 | CARTRIDGE-BASED IN-BORE INFUSER - A fluid delivery device includes: a fluid-filled cartridge comprising an outlet; a syringe comprising a substantially cylindrical syringe barrel having an open end and a fluid dispensing end; and a plunger rod configured to be received within the open end of the syringe barrel. The plunger rod comprises: a first end having a sealing member provided in sealing engagement with an inner wall of the syringe barrel such that a first syringe chamber is provided between the first end of the plunger rod and the fluid dispensing end of the syringe barrel; a second end extending out of the open end of the syringe barrel and having a cartridge-receiving chamber having a connection mechanism positioned therein for connecting the outlet of the cartridge thereto. The plunger rod also includes a fluid channel extending from the connection mechanism to the first end of the plunger rod. | 2020-05-14 |
20200147297 | STERILE TRANSFER OF FLUID - A syringe rack securable to a surface of a fixture and configured for facilitating a sterile transfer of fluid from a non-sterile environment to a sterile environment. The syringe rack includes a securing portion and a syringe-receiving station. The syringe-receiving portion is coupled to the securing portion and configured to receive the syringe in a selectively releasable coupling arrangement where the syringe is oriented such that an opening in a barrel of a syringe projects away from the fixture when the syringe is received by the syringe-receiving station and when the securing portion is secured to the surface of the fixture. | 2020-05-14 |
20200147298 | SELF-RIGHTING SYSTEMS AND RELATED COMPONENTS AND METHODS - Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent (e.g., for delivery to a location internal to a subject). | 2020-05-14 |
20200147299 | MRI-COMPATIBLE SURGICAL CANNULAE FOR TRANSFERRING A SUBSTANCE TO AND/OR FROM A PATIENT - A cannula for transferring a substance to and/or from a patient includes a tubular support sleeve and a transfer tube. The support sleeve includes a rigid tubular member defining a lumen extending from a proximal end to a distal end of the tubular member. The transfer tube is positioned in the lumen and extends beyond each of the proximal end and the distal end of the tubular member. The tubular member includes a rigid, MRI-compatible material. | 2020-05-14 |
20200147300 | FILTER FOR REDUCING PHENOLIC COMPOUNDS FROM INSULIN AND RELATED INFUSION AND INJECTION DEVICES - Provided herein are devices, systems, and methods for the removal of preservatives/excipients/stabilizers from pharmaceutical preparations/medicaments. The devices and systems include a resin for the filtering of preservatives from pharmaceutical preparations. The methods allow for a period of time of incubation of the pharmaceutical preparation in the resin that effectively removes preservatives, while at the same time maintaining the required amount or concentration of active compound in the preparation. Also provided herein are devices, systems, and methods for the controlled release of anti-inflammatory agents in an insulin infusion set. | 2020-05-14 |
20200147301 | SYSTEMS AND METHODS FOR DELIVERING BIOMATERIALS - Delivery systems and methods for forming and delivering biomaterials from two components are described herein. In particular, apparatus and methods for performing controlled delivery of multicomponent delivery of biomaterials into or onto a body part, such as a body lumen are described. More specifically, in some embodiments, the apparatus and methods are directed towards controlled delivery of micro-volumes of biomaterials into or onto a target location, the micro-volumes being defined as 0.001 mL-1 mL (or 1 μL-1,000 μL) of volume. | 2020-05-14 |
20200147302 | Implantable Infusion Devices Including Apparatus For Confirming Fluid Flow And Systems, Apparatus And Methods Associated With Same - Implantable infusion apparatus, systems and methods that involve the use of a sensor that is associated with the catheter outlet. | 2020-05-14 |
20200147303 | INFUSION PUMP CONTROL METHOD, INFUSION PUMP AND TUBE CASSETTE FOR FLUID DELIVERY - A method reads fluid delivery specification from a tube cassette and carry out infusion upon acceptance of the fluid delivery specification. An infusion pump comprises a housing having a compartment into which a tube cassette is receivable; a controller; a label reader disposed in the housing, accessible to the cassette compartment and coupled to the controller; a user interface disposed in the housing and coupled to the controller, the user interface including a screen, a first operator and a second operator coupled to the user interface. The first and second operators provide a first response signal to the controller for a prompt displayed on the screen and a second response signal to the controller for a request displayed on the screen. A tube cassette has a label bearing fluid delivery specification and allows fluid infusion upon the specification in the label matching parameters stored in an infusion pump. | 2020-05-14 |
20200147304 | MEDICAL DEVICE ANTENNA SYSTEMS HAVING EXTERNAL ANTENNA CONFIGURATIONS - A medical device includes an antenna external to a case, package, or encapsulant for the electronic systems of the medical device. In one embodiment, a diabetes infusion pump is enclosed within a metal case, the pump including a processor and a communication module for wireless communications. An antenna is disposed in the delivery tubing of the pump outside the case with an antenna feed interconnecting the external antenna with the internal communication module. In another aspect, a thin film antenna is formed on the outer surf ace of the case in which a physiological parameter sensor, such as a glucose sensor, is enclosed. Multiple antennas may be used for communications on different frequencies. | 2020-05-14 |
20200147305 | Infusion Pump System and Method - Some embodiments of an infusion pump system may be configured to allow the user to communicate with the infusion pump system using voice or image input. Optionally, particular embodiments can interpret the voice or image input using speech or image recognition capabilities. By incorporating speech or image recognition equipment within the infusion pump system, user interactions with the pump system can be enhanced and simplified. | 2020-05-14 |
20200147306 | METHODS FOR TREATING CONGENITAL HYPERINSULINISM - A method of treating congenital hyperinsulinism in a subject is disclosed. The method can include parenterally administering to the subject a first composition comprising a glucagon, a glucagon analogue, or a salt form of either thereof, and optionally administering to the subject a second composition comprising glucose, a glucose analogue, or a salt form of either thereof, wherein administration of the first composition sufficiently increases blood glucose level in the subject such that the second composition is not administered or the second composition is administered at a glucose infusion rate (GIR) of less than 8 mg/(kg*min). | 2020-05-14 |